Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lawmakers Begin Lobbying CMS Over Medicare Drug Formularies

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Smith (R-Ore.) expresses concern about classification of antidepressants in U.S. Pharmacopeia's Medicare formulary guidelines during Senate Finance Committee hearing.

You may also be interested in...



Lilly Honors Oregon Senator For Mental Health Legislation

Lilly's 2004 Helping Move Lives Forward Reintegration Government Honorary Award gives $5,000 to an advocacy program of the recipient's choice. Sen. Gordon Smith (R-Ore.) sponsored the Garrett Lee Smith Memorial Act, which boosts suicide prevention programs.

Lilly Honors Oregon Senator For Mental Health Legislation

Lilly's 2004 Helping Move Lives Forward Reintegration Government Honorary Award gives $5,000 to an advocacy program of the recipient's choice. Sen. Gordon Smith (R-Ore.) sponsored the Garrett Lee Smith Memorial Act, which boosts suicide prevention programs.

USP Responding To Congress' Questions On Medicare Formulary Guidelines

The U.S. Pharmacopeia has provided information to two congressional committees as it moves toward finalizing its model formulary guidelines for the Medicare drug benefit. USP emphasizes that no decision on the final structure of the guidelines has been made; final recommendations to CMS are expected by year-end.

Related Content

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel